Research & development decreased 32.4%
Research & development changed -32.4% from the comparable as-filed period.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Research & development changed -32.4% from the comparable as-filed period.
Revenue changed +1031.2% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a low base.
Net income changed -471.6% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
Gross profit changed +3101.7% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a low base.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.